Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare Program; Secure Electronic Prior Authorization for Medicare Part D [CMS-4819-P]” published in the Federal Register on June 19, 2019.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to its, “Request for Information; Reducing Administrative Burden To Put Patients Over Paperwork [CMS-6082-NC],” published in the Federal Register on June 11, 2019.
On July 23, Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-OR) released the Chairman’s Mark of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, bipartisan legislation to reduce health care costs. AMCP will continue to engage with staff on the Finance committee on these provisions as we have with Members and staff on the Senate Health, Education, Labor, and Pensions (HELP) Committee.
The Academy of Managed Care Pharmacy (AMCP) is pleased to share our thoughts on the “Lower Health Care Costs Act” (“the Act”) as released on May 23, 2019 by the Committee on Health, Education, Labor and Pensions (“HELP Committee”).
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of the National Coordinator for Health Information Technology (ONC) for the opportunity to provide comments in response to its proposed rule “21st Century Cures Act: Interoperability, Information Blocking, and the Health IT Certification Program” published in the Federal Register on March 4, 2019. AMCP appreciates ONC’s effort to remove barriers to interoperability and health information exchange.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to comment on its public hearing on Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products [FDA-2019-N-1132].
As stakeholders that support patient access to affordable medicines and competition in the pharmaceutical marketplace, we applaud the Food and Drug Administration’s (FDA) efforts to foster the development of biosimilar medicines for America’s patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the updated draft industry guidance on “Nonproprietary Naming of Biological Products” published in the Federal Register on March 8, 2019. AMCP appreciates FDA’s ongoing efforts to issue and update guidance that allow health care providers to safely and effectively use biosimilar products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services Office of Inspector General (HHS-OIG) for the opportunity to provide comments in response to the proposed rule titled “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of a New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees [OIG-0936-P]” published in the Federal Register on February 6, 2019.
AMCP writes to request your veto on House Bill 435 which implements an exception process for coverage of a drug removed from a formulary at the previous cost sharing level. Imposing government mandated restrictions on formularies as outlined in the bill could have the unintended consequence of raising the overall cost of health care coverage for patients.
